NCT07057427 2025-07-09
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Henan Cancer Hospital
Phase 3 Recruiting
Clinical Trials
10 trialsNCT06927180 2025-06-23
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Phase 2 Recruiting
NCT01785420 2025-04-09
Pre Operative Trastuzumab in Operable Breast Cancer
Tata Memorial Hospital
Phase 3 Recruiting
NCT03950271 2024-02-28
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT05474690 2024-02-26
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Henan Cancer Hospital
Phase 3 Withdrawn
NCT03735966 2022-12-01
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Henan Cancer Hospital
Phase 2 Completed
NCT03947242 2019-05-15
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
Henan Cancer Hospital
Phase NA Unknown
NCT01472146 2017-05-09
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Instituto Nacional de Cancer, Brazil
Phase 2 Completed
NCT02062983 2016-05-13
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
National Guard Health Affairs
Suspended
NCT00532857 2012-01-04
PGH
National Cancer Center, Korea
Phase 2 Completed